Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
NCT06774625Phase 2Completed
- Sponsor
- Latigo Biotherapeutics
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LTG-001 in acute postoperative pain (5 arms), sponsored by Latigo Biotherapeutics. Primary endpoint: Sum of Pain Intensity Differences over 0 to 12 hours. Started Dec 2024; status: completed.
02
Drugs
LTG-001
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on NCT06774625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774625.